Sun Pharmaceutical Industries has reported financials for the third quarter ending December 31, 2012. The pharma major's third quarter net sales rose 32 percent from a year ago to Rs 2,852 crore.
Mr Dilip Shanghvi, managing director, Sun Pharmaceutical Industries said, "All our businesses continue to perform in-line with our expectations. The recent approval of our generic Doxorubicin HCl Liposomal Injection in the US reflects our technological strengths in developing complex products. The acquisition of DUSA and URL's generic business will further strengthen our presence in the US. Overall, we shall strive to remain focused on execution and building a business with consistent performance."